In women, bisphosphonate use for ≥3 years vs. <3 months was linked to increased atypical femur fracture risk

被引：0
|
作者：
Ott, Susan M. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2021年 / 174卷 / 01期
关键词：
D O I：
10.7326/ACPJ202101190-009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：JC9 / JC9
页数：1
相关论文
共 41 条
  • [1] Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years
    Joan C. Lo
    Romain S. Neugebauer
    Bruce Ettinger
    Malini Chandra
    Rita L. Hui
    Susan M. Ott
    Christopher D. Grimsrud
    Monika A. Izano
    BMC Musculoskeletal Disorders, 21
  • [2] Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years
    Lo, Joan C.
    Neugebauer, Romain S.
    Ettinger, Bruce
    Chandra, Malini
    Hui, Rita L.
    Ott, Susan M.
    Grimsrud, Christopher D.
    Izano, Monika A.
    BMC MUSCULOSKELETAL DISORDERS, 2020, 21 (01)
  • [3] The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy
    Lo, Joan C.
    Hui, Rita L.
    Grimsrud, Christopher D.
    Chandra, Malini
    Neugebauer, Romain S.
    Gonzalez, Joel R.
    Budayr, Amer
    Lau, Gene
    Ettinger, Bruce
    BONE, 2016, 85 : 142 - 147
  • [4] Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center
    J. H. Koh
    J. P. Myong
    J. Yoo
    Y.-W. Lim
    J. Lee
    S.-K. Kwok
    S.-H. Park
    J. H. Ju
    Osteoporosis International, 2017, 28 : 3251 - 3259
  • [5] Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center
    Koh, J. H.
    Myong, J. P.
    Yoo, J.
    Lim, Y. -W.
    Lee, J.
    Kwok, S. -K.
    Park, S. -H.
    Ju, J. H.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (11) : 3251 - 3259
  • [6] Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture
    Hiligsmann, Mickael
    Williams, Setareh A.
    Fitzpatrick, Lorraine A.
    Silverman, Stuart S.
    Weiss, Richard
    Reginster, Jean-Yves
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (02) : 184 - 196
  • [7] Comparison of the Use of the EPDS-3 vs. EPDS-10 to Identify Women at Risk for Peripartum Depression
    Bodenlos, Kimberly L.
    Maranda, Louise
    Deligiannidis, Kristina M.
    OBSTETRICS AND GYNECOLOGY, 2016, 127 : 89S - 90S
  • [8] Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation
    van de Laarschot, Denise M.
    Zillikens, M. Carola
    BONE, 2016, 91 : 148 - 151
  • [9] Cytomegalovirus prevention in high risk lung transplant recipients: Comparison of 3 months vs. 12 months valganciclovir therapy
    Jaksch, P. T. H.
    Zweytick, B.
    Lang, G.
    Hoda, A.
    Keplinger, M.
    Gaugg, M.
    Klepetko, W.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2008, 27 (02): : S103 - S103
  • [10] Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation
    Pedersen, Alma B.
    Heide-Jorgensen, Uffe
    Sorensen, Henrik T.
    Prieto-Alhambra, Daniel
    Ehrenstein, Vera
    JAMA NETWORK OPEN, 2019, 2 (04)
12345